-

Dexcom Appoints Karen Dahut to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.

Ms. Dahut has more than 25 years of leadership experience in technology, cyber, and analytics, including the development and execution of innovative growth strategies. She currently serves as a member of the executive leadership team at Booz Allen Hamilton, a leading global consulting firm to business, government, and military clients. Ms. Dahut serves as Group Leader of the Global Commercial and Global Defense businesses, reporting directly to the CEO and overseeing approximately 12,000 employees. In this role, she leads the strategy and delivery of the firm’s solutions to a broad array of clients, including several Fortune 100 companies. Ms. Dahut brings to the Dexcom Board a successful track record of transformational leadership and entrepreneurial creativity in areas with direct relevance to Dexcom’s future growth opportunities.

“We are very excited to announce the appointment of Karen to the Dexcom Board,” said Kevin Sayer, chairman, president and CEO at Dexcom. “Karen has demonstrated the value of her leadership throughout her career, including the establishment of Booz Allen Hamilton’s Strategic Innovation Group focused on next generation cybersecurity, cloud, data science and digital technologies. Her experience provides a natural fit as we look to maintain our leadership in data connectivity and analytics and extend the applications of Dexcom’s real-time CGM systems to more people throughout the world.”

About Karen Dahut

Karen Dahut is an Executive Vice President and Senior Partner at Booz Allen Hamilton, where she serves as Group Leader of the firm’s Global Commercial and Global Defense Business. Prior to assuming this role in 2017, Ms. Dahut held several additional roles throughout the organization, including: Group Leader, Global Commercial and Federal Civilian Business from 2015 to 2017; Chief Innovation Officer from 2012 to 2015; Leader, Analytics and Data Science Business from 2010 to 2012; Market Leader, Worldwide Navy and Marine Corps Business from 2008 to 2010; Leader, Economic and Business Analytics Capability from 2005-2008; and various additional roles from 2002 to 2005. Prior to her time at Booz Allen Hamilton, Ms. Dahut served as the Program Director, Logistics Management Institute from 1991 to 2002 and as a United States Naval Officer from 1985 to 1991.

In addition to her experience as a transformational business leader, Ms. Dahut is an accomplished speaker and author. In 2019, she was selected as the C-Suite Executive of the Year by Washington Business Journal. She is currently on the Board of Directors for the National Air and Space Museum and Northern Virginia Technology Council. She previously served on the Board of Directors of Tech Data Corporation, an end-to-end technology distributor and Fortune 100 company, prior to its acquisition by Apollo Global Management in 2020. Ms. Dahut holds an MS from the University of Southern California’s Viterbi School of Engineering and a bachelor’s degree in Finance from Mount Saint Mary’s University.

About DexCom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

DexCom, Inc.:
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
(858) 200-0200
www.dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Summary
Dexcom Appoints Karen Dahut to Board of Directors
Release Versions

Contacts

DexCom, Inc.:
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
(858) 200-0200
www.dexcom.com

More News From DexCom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom